Beijing Minhai Biotechnology Co., Ltd
18
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
61%
11 trials in Phase 3/4
0%
0 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)
Role: lead
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Role: lead
A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants
Role: lead
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years
Role: lead
Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)
Role: collaborator
Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)
Role: collaborator
A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)
Role: collaborator
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Role: lead
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
Role: lead
A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Role: collaborator
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
Role: collaborator
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.
Role: collaborator
Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
Role: collaborator
The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
Role: collaborator
Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried
Role: lead
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
Role: lead
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
Role: lead
Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China
Role: collaborator
All 18 trials loaded